01- Novel DES Technology Promises to Become the Next DES Generation
The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing.
Read more HERE
02- The Fellow’s Corner | 3rd Clinical Case: True Bifurcation Lesion: Which Strategy Should We Use?
Here is the third Fellow’s Corner clinical case to keep discussing and learning alongside the entire community of hemodynamics fellows in Latin America.
Read more HERE
03- Ticagrelor or Prasugrel for Acute Patients Who Undergo Angioplasty
We are still asking the same question: ticagrelor or prasugrel? With narrow margins between these drugs in terms of efficacy and bleeding, it is difficult to decide which to prescribe.
Read more HERE
04- Could Statins Do More than Lower Cholesterol in COVID-19 Patients?
A history of acute myocardial Infarction, cardiac failure or hyperlipidemia has been associated with increased mortality of COVID-19.
Read more HERE
05- Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease
Three randomized studies showed exercising significantly improves 6-minute walk outcomes in patients with peripheral artery disease (PAD). However, many participants randomized to exercise did not perceive changes, and sometimes even got worse.
Read more HERE
06- SOLACI Research | Invitation to Participate in the Latin American SOLACI Peripheral Registry
After much effort, SOLACI Research is pleased to formally invite the entire community to participate in the Latin American SOLACI Peripheral Registry, our second research initiative.
Read more HERE
07- How Bad is Malapposition? OCT Findings and Events
Most post-angioplasty findings with optical coherence tomography (OCT) were not associated with clinical adverse events. Exceptions were small intra-stent area, and significant malapposition.
Read more HERE
08- Anosmia 1 Year After a COVID-19 Diagnosis
The number of people with post-COVID-19 syndrome seems to be growing exponentially, so we need long-term data to help physicians advise patients correctly.
Read more HERE
09- Efficacy of the Novavax Vaccine Against COVID-19: Nanoparticle Technology to the Test
In healthy adults, two doses of the NVX-CoV2373 (Novavax) vaccine has an efficacy of almost 90% against SARS-CoV-2 infection in all severity types. Furthermore, it has proven to be effective against the alpha variant (B.1.1.7).
Read more HERE
10- Janssen: Efficacy of the Only Single Dose Vaccine against COVID-19
One single dose of the Ad26.COV2.S vaccine (Janssen) will protect you against symptomatic and asymptomatic SARS-CoV-2 infection. It also resulted effective to prevent severe or critical COVID-19, including hospitalization and death. Safety outcomes resulted similar to other COVID-19 vaccine phase 3 outcomes.
Read more HERE
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology